Metformin May Enhance COVID-19 Survival for Diabetes Patients
For many years, metformin has been the preferred medication for managing blood sugar levels in individuals with type 2 diabetes. Recent research from Stanford University has indicated that this diabetes medication might have additional benefits, particularly for those who contract COVID-19.
Study Findings
The study, which analyzed the medical records of 53,332 U.S. adults with type 2 diabetes, found that those who were prescribed metformin prior to a COVID-19 diagnosis had a 39% lower risk of dying within a year following their infection compared to those on other diabetes medications known as dipeptidyl peptidase-4 inhibitors (DPP4i).
Understanding the Mechanism
High blood sugar levels can impair immune responses, a consequence highlighted by the Centers for Disease Control and Prevention (CDC). Metformin is known for its ability to lower blood sugar and enhance insulin sensitivity, but researchers are still examining whether these factors directly relate to improved survival rates in COVID-19 patients.
Additionally, scientists suggest that metformin may influence biological pathways related to blood pressure and fluid balance, which could impact COVID-19 severity. Prior studies have also noted its anti-inflammatory properties, which could be beneficial during viral infections.
Research Methodology
In this study, patients examined ranged in age from 30 to 85, all having tested positive for COVID-19 between October 2021 and November 2023. Among them, 50,965 were on metformin, while 2,367 had been prescribed DPP4 inhibitors. The average age of metformin users was 60, compared to 64 for those on DPP4 inhibitors.
Adjustments and Outcomes
After accounting for variables such as age and gender, the data indicated that the metformin group had a significantly improved survival rate in the year following their COVID-19 diagnosis. However, researchers emphasize that this study does not establish a direct causal relationship between metformin usage and increased survival.
Notably, there was an initial indication of a 13% reduction in long COVID symptoms among metformin users, but subsequent analyses showed this correlation was not statistically significant.
Further Research Needed
Other studies have echoed similar findings, such as research from the University of Minnesota Medical School, suggesting metformin taken shortly after a COVID-19 diagnosis could lead to lower mortality and a reduced chance of developing long COVID. Nevertheless, the call for more robust clinical trials remains strong to better understand these potential benefits.
“There is some evidence from the same group that metformin, started early in a COVID infection, may lower the risk of long COVID, but that still needs to be confirmed in large, well-designed randomized trials,” said Dr. Ziyad Al-Aly, a senior clinical epidemiologist.
Considerations for Patients
While the findings are promising, experts caution not to alter current medications based on this study alone. Patients prescribed DPP4 inhibitors often have additional health conditions or age-related factors that necessitate their specific medication choice.
“This is not enough evidence to change treatment,” Dr. Al-Aly added. “If you take either drug, do not change it because of this study.”
